NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
June 20 2018 - 9:00AM
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that
updated data for patients with diffuse intrinsic pontine glioma
(DIPG) from NLG2105, a Phase 1 study evaluating indoximod in
combination with radiation and chemotherapy for the treatment of
pediatric patients with progressive brain tumors, will be presented
at the International Symposium on Pediatric Neuro-Oncology (ISPNO)
in Denver, Colorado. The presentation session and time are
noted below.
- Poster Session 1: IMMU-25 – Radio-immunotherapy using the IDO
pathway inhibitor indoximod for children with newly-diagnosed DIPG,
to be presented by Theodore S. Johnson, M.D., Ph.D., Georgia Cancer
Center, Augusta University, Sunday, July 1, 5:00PM – 6:30PM MT,
Hyatt Regency Denver
About Indoximod
Indoximod is an investigational, orally
available small molecule targeting the IDO pathway. The IDO pathway
is a key immuno-oncology target involved in regulating the tumor
microenvironment and immune escape. Indoximod is being
evaluated in combination with treatment regimens including
chemotherapy, radiation, checkpoint blockade and cancer vaccines
across multiple indications such as AML, DIPG and melanoma.
About NewLink Genetics
Corporation
NewLink Genetics is a clinical stage
biopharmaceutical company focusing on discovering, developing and
commercializing novel immuno-oncology product candidates to improve
the lives of patients with cancer. NewLink Genetics' IDO pathway
inhibitors are designed to harness multiple components of the
immune system to combat cancer. For more information, please
visit www.newlinkgenetics.com and follow us on Twitter
@NLNKGenetics.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains forward-looking
statements of NewLink Genetics that involve substantial
risks and uncertainties. All statements contained in this press
release are forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. The words "will,"
“to be,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among
others, statements about results of NewLink’s clinical trials for
product candidates and any other statements other than statements
of historical fact. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that NewLink Genetics
makes due to a number of important factors, including those risks
discussed in "Risk Factors" and elsewhere in NewLink
Genetics' Annual Report on Form 10-K for the year
ended December 31, 2017 and other reports filed with
the U.S. Securities and Exchange Commission (SEC). The
forward-looking statements in this press release
represent NewLink Genetics’ views as of the date of this
press release. NewLink Genetics anticipates that
subsequent events and developments will cause its views to change.
However, while it may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing NewLink
Genetics' views as of any date subsequent to the date of this
press release.
Investor Contact:
Lisa MillerDirector of Investor RelationsNewLink
Genetics515-598-2555lmiller@linkp.com
Media Contact:
Sharon CorreiaVP, Integrated
CommunicationsLaVoieHealthScience617-374-8800, ext.
105scorreia@lavoiehealthscience.com
Source: NewLink Genetics Corporation
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NewLink Genetics (NASDAQ:NLNK)
Historical Stock Chart
From Apr 2023 to Apr 2024